Precigen, Inc. announced on March 25 its full year 2025 financial results and provided business updates following the launch of its first commercial product, PAPZIMEOS. The company said it transitioned from a clinical-stage to a commercial-stage biopharmaceutical firm during the year, marking what leadership described as a transformational period.
The update is significant for stakeholders as it details Precigen’s shift to revenue generation through the commercialization of PAPZIMEOS, which is now being adopted as a first-line standard of care for adults with recurrent respiratory papillomatosis (RRP). Helen Sabzevari, President and CEO of Precigen, said, “With the FDA approval and launch of PAPZIMEOS, 2025 marked a transformational year for Precigen as we transitioned from a clinical-stage to a commercial-stage company and recognized our first commercial product revenues toward the end of the year.” She added that there is strong alignment among physicians regarding PAPZIMEOS due to its status as the only approved therapy for RRP.
Phil Tennant, Chief Commercial Officer at Precigen, reported growing physician adoption since approval in August. “Since deploying our full field organization, we have engaged all target medical institutions and are seeing prescriptions and active treatment across the United States in both major medical centers and community practices. Patient hub enrollment has surpassed 300 patients… while payer coverage now extends to approximately 215 million lives across private insurers, as well as Medicare and Medicaid,” Tennant said.
Harry Thomasian Jr., Chief Financial Officer at Precigen, discussed financial outcomes: “2025 was a game-changing year for Precigen with the FDA approval of PAPZIMEOS… Our first sale of PAPZIMEOS was recorded in the fourth quarter of 2025 and we are encouraged by continued revenue momentum we’re seeing as we begin the new year.” Total revenues increased by $5.8 million compared to last year primarily due to new product sales. Research and development expenses decreased by $11.7 million due in part to operational changes made in previous years; however selling, general and administrative expenses rose by $28.8 million mainly because of costs related to commercialization efforts.
The company also noted impairment charges connected with prior operational suspensions and changes in valuation linked mostly to an increase in common stock price during valuation periods. All outstanding preferred shares were converted into common shares on September 15, leading to non-cash accounting adjustments impacting net loss calculations.
Looking ahead, Thomasian Jr. said that based on current forecasts from ongoing sales activity they expect their cash position will fund operations through break-even by end-2026.
PR Newswire operates globally with services including press release distribution across more than 170 countries in over 40 languages according to its official website. The network collaborates with over half a million media outlets worldwide according to PR Newswire, offering clients AI-enhanced content tools alongside editorial support available around-the-clock as outlined online.
